What is the safest and most effective contraception for a woman with von Willebrand disease type 2A?

Contraception for Women with Von Willebrand Disease Type 2A

Combined hormonal contraceptives (CHCs) are the first-line contraceptive option for women with von Willebrand disease type 2A, offering both effective contraception and management of heavy menstrual bleeding, which is a predominant symptom in this population. 1

Primary Recommendation: Combined Hormonal Contraceptives

CHCs serve a dual purpose in women with VWD type 2A:

• Contraceptive efficacy: Highly effective pregnancy prevention
• Therapeutic benefit: First-line treatment for menorrhagia, which affects 32-100% of women with VWD 2
• Safety profile: Recent meta-analysis demonstrates that COCs do not significantly alter VWF% or FVIII% levels (VWF%: 2.62,95%CI -0.59 to 5.83, p=0.40; FVIII%: 2.99,95%CI -4.85 to 10.82, p=0.46), and importantly, do not interfere with accurate VWD diagnosis 3

The evidence strongly supports that CHCs can be used safely without concern for masking disease severity or complicating diagnostic testing.

Alternative Contraceptive Options

Levonorgestrel Intrauterine System (LNG-IUD)

The LNG-IUD represents a reasonable alternative, though with important caveats:

• Potential benefit: Can reduce menstrual bleeding over time 4
• Critical caveat: One case report documented initial worsening of menorrhagia from 8 to 14 consecutive days monthly after LNG-IUD placement in a woman with undiagnosed mild VWD, though bleeding eventually improved to spotting by 19 months 5
• Practical consideration: Requires patient counseling about potential initial worsening of bleeding before improvement occurs
• Management of bleeding irregularities: Per 2024 CDC guidelines, no specific interventions are identified for LNG-IUD users experiencing bleeding irregularities 6

Copper Intrauterine Device (Cu-IUD)

The Cu-IUD should generally be avoided as it can worsen menorrhagia, which is already problematic in VWD type 2A patients. If used and bleeding occurs, NSAIDs for 5-7 days are the recommended intervention 6.

Progestin-Only Methods

• Injectable DMPA: Can be considered, with NSAIDs for 5-7 days available to manage spotting or light bleeding 6
• Implants: Acceptable option, with multiple treatment strategies available for bleeding irregularities including NSAIDs, hormonal treatment (low-dose COCs or estrogen for 10-20 days), or antifibrinolytic agents like tranexamic acid for 5 days 6

Clinical Algorithm for Selection

1. First choice: Combined hormonal contraceptives (oral, patch, or ring)

   • Addresses both contraception and menorrhagia simultaneously
   • No interference with VWF/FVIII levels or disease monitoring

2. Second choice: LNG-IUD

   • For patients who prefer long-acting reversible contraception
   • Counsel about potential initial bleeding worsening
   • Plan for close follow-up during first 6-12 months

3. Third choice: Progestin-only methods (implant or DMPA)

   • When estrogen is contraindicated
   • Have treatment plan ready for breakthrough bleeding

4. Avoid: Copper IUD

   • Risk of exacerbating menorrhagia

Important Considerations for Type 2A Specifically

Type 2A VWD tends to present with greater clinical severity than other type 2 variants, with prominent mucocutaneous bleeding including heavy menstrual bleeding 7. This makes the therapeutic benefit of CHCs particularly valuable in this subtype. The selective reduction of high- and intermediate-molecular-weight multimers in type 2A results in impaired hemostasis under high shear stress 7, making bleeding control a priority alongside contraception.

Collaborative Management

Collaboration with a hematologist is essential for long-term management of women with VWD type 2A 1. This ensures coordinated care for both contraceptive management and bleeding disorder treatment, particularly if breakthrough bleeding occurs or surgical interventions become necessary.